We report a case of abnormal meniscal-like anterior cruciate ligament (ACL), inserting at the 9 o’clock position just beside the cartilage of the lateral femoral condyle, in a stable knee associated with osteochondri...We report a case of abnormal meniscal-like anterior cruciate ligament (ACL), inserting at the 9 o’clock position just beside the cartilage of the lateral femoral condyle, in a stable knee associated with osteochondritis dissecans (OCD) of the medial femoral condyle.展开更多
In the last few years,the success of anti-PD1 and anti-PDL1 drugs in solid cancers treatment and the advances in molecular biology have provided new potential treatment strategies for patients with metastatic colorect...In the last few years,the success of anti-PD1 and anti-PDL1 drugs in solid cancers treatment and the advances in molecular biology have provided new potential treatment strategies for patients with metastatic colorectal cancer.Unfortunately,only patients with mismatch repair deficiency seem to benefit from immunotherapy and they represent a small subset of the metastatic population.New ongoing studies focus on converting an immune ignorant tumour into an inflamed one by combination therapies and on introducing an immunotherapeutic approach in earlier stages of disease(neoadjuvant and adjuvant setting).In this review we summarize the current knowledge about the molecular and immune landscape of colorectal cancer and propose new potential combination strategies to enhance the efficacy of immunotherapy.展开更多
文摘We report a case of abnormal meniscal-like anterior cruciate ligament (ACL), inserting at the 9 o’clock position just beside the cartilage of the lateral femoral condyle, in a stable knee associated with osteochondritis dissecans (OCD) of the medial femoral condyle.
文摘In the last few years,the success of anti-PD1 and anti-PDL1 drugs in solid cancers treatment and the advances in molecular biology have provided new potential treatment strategies for patients with metastatic colorectal cancer.Unfortunately,only patients with mismatch repair deficiency seem to benefit from immunotherapy and they represent a small subset of the metastatic population.New ongoing studies focus on converting an immune ignorant tumour into an inflamed one by combination therapies and on introducing an immunotherapeutic approach in earlier stages of disease(neoadjuvant and adjuvant setting).In this review we summarize the current knowledge about the molecular and immune landscape of colorectal cancer and propose new potential combination strategies to enhance the efficacy of immunotherapy.
